| The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. | The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.
Talia M, Cirillo F, Spinelli A, Zicarelli A, Scordamaglia D, Muglia L, De Rosis S, Rigiracciolo DC, Filippelli G, Perrotta ID, Davoli M, De Rosa R, Macirella R, Brunelli E, Miglietta AM, Nardo B, Tosoni D, Pece S, De Francesco EM, Belfiore A, Maggiolini M, Lappano R., Free PMC Article | 07/13/2023 |
| Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting. | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting.
Wang L, Tang S, Yu Y, Lv Y, Wang A, Yan X, Li N, Sha C, Sun K, Li Y. | 11/6/2021 |
| EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer. | EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer.
Kim SH, Kang BC, Seong D, Lee WH, An JH, Je HU, Cha HJ, Chang HW, Kim SY, Kim SW, Han MW., Free PMC Article | 09/25/2021 |
| Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics. | Critical role of EphA3 in cancer and current state of EphA3 drug therapeutics.
London M, Gallo E. | 06/12/2021 |
| Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3. | Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3.
Chen X, Zhang L, Yuan M, Kuang Z, Zou Y, Tang T, Zhang W, Hu X, Xia T, Cao T, Jia H. | 05/15/2021 |
| EphA3 promotes the proliferation of NPC cells through negatively regulating the ability of FOG2. | EphA3 promotes the proliferation of NPC cells through negatively regulating the ability of FOG2.
Song Z, Gao S, Liu YM, Wang Y, Sun ZX, Bao D, Liu C. | 04/17/2021 |
| Increased EphA3 expression is an independent prognostic factor for a poor outcome and decreased survival in prostate cancer patients treated with radical prostatectomy.EphA3 expression in the prostate cancer was correlated with the pathological stage, bladder and rectal invasion, distant metastasis. | The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy.
Duan X, Xu X, Yin B, Hong B, Liu W, Liu Q, Tao Z., Free PMC Article | 12/14/2019 |
| Hypermethylation of a CpG island within the EPHA3 promoter provides a possible mechanism for loss of EphA3 expression and was associated with lymph node metastasis and TNM stage in colorectal cancer. | EphA3 Downregulation by Hypermethylation Associated with Lymph Node Metastasis and TNM Stage in Colorectal Cancer.
Wang Y, Xuan Z, Wang B, Zhang D, Zhang C, Wang J, Sun Y. | 11/23/2019 |
| EphA3 is a target of miR-340, and ectopic expression of EphA3 can promote the migration and invasion of cervical cancer cells, whereas restoration of EphA3 in miR-340-overexpressing cervical cancer cells reversed the suppressive effects of miR-340. | MiR-340 suppresses the metastasis by targeting EphA3 in cervical cancer.
Xiao H, Yu L, Li F, Wang H, Li W, He X. | 11/9/2019 |
| EphA3 mediated the tumor invasiveness and migration in radioresistant head and neck cancer cell lines and epithelial mesenchymal transition- related protein expression. Inhibition of EphA3 enhanced radiosensitivity in the AMC HN 3R cell line in vitro and in vivo study. | EphA3 maintains radioresistance in head and neck cancers through epithelial mesenchymal transition.
Kim SH, Lee WH, Kim SW, Je HU, Lee JC, Chang HW, Kim YM, Kim K, Kim SY, Han MW. | 09/21/2019 |
| we show that EPHA2 and EPHA3 together mark a GBM stem cells (GSC) population in treatment-refractory, recurrent Glioblastoma (rGBM) and that strategic cotargeting of EPHA2 and EPHA3 presents a novel and rational therapeutic approach for rGBM. | Cotargeting Ephrin Receptor Tyrosine Kinases A2 and A3 in Cancer Stem Cells Reduces Growth of Recurrent Glioblastoma.
Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu A, Gorelik M, Subapanditha MK, Savage N, Yang J, Chokshi C, London M, Gont A, Bobrowski D, Grinshtein N, Brown KR, Murty NK, Nilvebrant J, Kaplan D, Moffat J, Sidhu S, Singh SK. | 09/21/2019 |
| the regulation of EphA3 expression plays a critical role in glioblastoma cell growth in non-adherent conditions. | EphA3 is up-regulated by epidermal growth factor and promotes formation of glioblastoma cell aggregates.
Toyama M, Hamaoka Y, Katoh H. | 09/14/2019 |
| silencing EphA3 in KYSE410 cells triggered epithelialmesenchymal transition, and promoted cell migration and invasion. These results suggested that EphA3 may serve a tumorsuppressor role in esophageal squamous cell carcinoma. | EphA3 inhibits migration and invasion of esophageal cancer cells by activating the mesenchymal‑epithelial transition process.
Chen X, Lu B, Ma Q, Ji CD, Li JZ. | 04/6/2019 |
| High EPHA3 expression is associated with tumor growth and angiogenesis in gastric cancer. | EphA3 contributes to tumor growth and angiogenesis in human gastric cancer cells.
Lv XY, Wang J, Huang F, Wang P, Zhou JG, Wei B, Li SH. | 11/24/2018 |
| To investigate the relationship between five EPHA3 single nucleotide polymorphisms (SNPs) and Nonsyndromic Cleft Lip With or Without Cleft Palate (NSCL/P), EPHA3 SNPs (rs7650466, rs1398197, rs17801309, rs1054750, and rs7632427) were genotyped. The rs7650466 T allele was associated with the incidence of NSCL/P as well as with protective and dominant effects in both conditions. | Association of EPHA3 Gene Polymorphisms with Nonsyndromic Cleft Lip With or Without Cleft Palate.
Chen R, Guo S, Wang X, Mu Y, Duan E, Xu Y. | 11/3/2018 |
| Although EPHA3 was reported to be one of the most frequently mutated genes in colorectal tumors, our studies using inducible isogenic cell line systems, mouse models and large human tumor collections, did not reveal a major role of this EPH receptor on proliferation/motility/invasion of cancer cells, tumor initiation/progression/metastasis in mouse models or survival of colorectal cancer patients. | Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer.
Andretta E, Cartón-García F, Martínez-Barriocanal Á, de Marcondes PG, Jimenez-Flores LM, Macaya I, Bazzocco S, Bilic J, Rodrigues P, Nieto R, Landolfi S, Ramon Y Cajal S, Schwartz S, Brown A, Dopeso H, Arango D., Free PMC Article | 10/20/2018 |
| The interaction of AR and SP1 contributes to regulate EPHA3 expression. | Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
Diao X, Chen X, Pi Y, Zhang Y, Wang F, Liu P, Gao Y, Wang X, Yang S, Lu S. | 10/13/2018 |
| Findings suggest that EPH receptor A3 (EphA3) plays an important role in the pathogenesis of multiple myeloma (MM). | EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.
La Rocca F, Airoldi I, Di Carlo E, Marotta P, Falco G, Simeon V, Laurenzana I, Trino S, De Luca L, Todoerti K, Villani O, Lackmann M, D'Auria F, Frassoni F, Neri A, Del Vecchio L, Musto P, Cilloni D, Caivano A. | 07/7/2018 |
| Study shows that EphA3 is highly overexpressed in multiple myeloma (MM) and provides evidence that EphA3 plays an important role in MM angiogenesis. | Epha3 acts as proangiogenic factor in multiple myeloma.
Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Famigliari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D., Free PMC Article | 03/10/2018 |
| Results indicate that EphA3 protein expression is reduced in clear-cell renal cell carcinoma, suggesting the possibility that this receptor functions as a tumor suppressor in this disease. | Loss of EphA3 Protein Expression Is Associated With Advanced TNM Stage in Clear-Cell Renal Cell Carcinoma.
Wang X, Xu H, Cao G, Wu Z, Wang J. | 10/28/2017 |
| EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic signaling pathways. | EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways.
Li M, Yang C, Liu X, Yuan L, Zhang F, Wang M, Miao D, Gu X, Jiang S, Cui B, Tong J, Yu Z. | 08/12/2017 |
| Data indicate that EPHA3 is involved in regulating the multidrug resistance (MDR) of small cell lung cancer (SCLC) via PI3K/BMX/STAT3 signaling and may be a therapeutic target in SCLC. | EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J, Wang Q, Liu H, Ye M, Wu X, Guo L., Free PMC Article | 02/18/2017 |
| PTP-PEST regulates EphA3 activation both by affecting cytoskeletal remodelling and through its direct action as a PTP controlling EphA3 phosphorylation. | PTP-PEST controls EphA3 activation and ephrin-induced cytoskeletal remodelling.
Mansour M, Nievergall E, Gegenbauer K, Llerena C, Atapattu L, Hallé M, Tremblay ML, Janes PW, Lackmann M. | 12/17/2016 |
| This study showed that EPHA3 gene involved in neuronal growth and cerebellum development and associated with neurological and psychological disorders. | The association of DNA methylation and brain volume in healthy individuals and schizophrenia patients.
Liu J, Siyahhan Julnes P, Chen J, Ehrlich S, Walton E, Calhoun VD., Free PMC Article | 10/1/2016 |
| A novel association between the EPHA3 deletion and prostate cancer risk was observed in Finnish individuals. | Germline copy number variation analysis in Finnish families with hereditary prostate cancer.
Laitinen VH, Akinrinade O, Rantapero T, Tammela TL, Wahlfors T, Schleutker J. | 05/21/2016 |